Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Biological: PRM-151Other: Placebo
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT01254409
- Locations
- 🇺🇸
Duke Clinical Research Unit, Durham, North Carolina, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇳🇱Center for Human Drug Research, Leiden, Netherlands
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01254331
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01253564
- Locations
- 🇨🇭
CHUV; Departement d'Oncologie, Lausanne, Switzerland
🇨🇭Universitätsspital Zürich; Dermatologische Klinik, Zürich, Switzerland
A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: DMARD
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT01251120
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 688
- Registration Number
- NCT01250119
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
- First Posted Date
- 2010-11-30
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 494
- Registration Number
- NCT01250379
A Study of RO5185426 in Patients With Metastatic Melanoma
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 374
- Registration Number
- NCT01248936
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Drug: Ocrelizumab-matching placeboDrug: Interferon beta-1a-matching placebo
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 821
- Registration Number
- NCT01247324
- Locations
- 🇺🇸
Northwestern University; Dept. of Neurology, Chicago, Illinois, United States
🇺🇸The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
🇺🇸Uni of Vermont Medical Center;, Burlington, Vermont, United States
A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
- Conditions
- Coronary Heart Disease, Graft Occlusion, Vascular
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 384
- Registration Number
- NCT01245634
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT01245439